dataesr/scientific-paragraphs-categorization huggingface dataset:
III. LEARNING FROM NOISE-FREE DATA A. Assumption on set D We consider throughout this section system (1) with d " 0 and a noise-free dataset D in (3). We define U 0 :" " up0q upT s q ¨¨¨uppT ´1qT s q ‰ P R mˆT , (4a) X 0 :" " xp0q xpT s q ¨¨¨xppT ´1qT s q ‰ P R nˆT , (4b) X 1 :" " 9 xp0q 9 xpT s q ¨¨¨9 xppT ´1qT s q ‰ P R nˆT. (4c) We assume a condition on the richness of the data. Assumption 1: The matrix " U0 X0 ‰ has full row rank. l Assumption 1 can be easily checked for a given set D. For discrete-time systems, when pu, dq is persistently exciting then Assumption 1 holds  [16]  (for an extension of this result to continuous-time systems see  [31] ). We will elaborate more on Assumption 1 in the discussion following Theorem 1 and at the beginning of Section IV.
His work is supported by the project  Digital Twin , number  P18-03 , of the research programme  TTW Perspective  which is (partly) financed by the  Dutch Research Council (NWO). His work is supported by  ANR  via grant  HANDY , number  ANR-18-CE40-0010. His work is supported by the  European Union  under the  Italian National Recovery and Resilience Plan  ( NRRP ) of NextGenerationEU, partnership on "Telecommunications of the Future"  ( PE00000001   -program  " RESTART "). E-.
In contrast, the IM21. 7c imidazolium-LNP was much more efficient at achieving higher expression in the lung with 6x10 6 versus 1x10 5 RLU/mg of proteins measured by luciferase assay, emphasising a significant difference in biodistribution between the two formulations. We also evaluated intramuscular (IM) delivery of the IM21. 7c-based LNP, which was as effective as a cationic liposome-based formulation used as a positive control (in vivo-jetRNA®+, Polyplustransfection) (data not shown). As some cationic lipids used in cationic liposomes or lipoplexes have been reported to induce some toxicity  [29]  (mainly liver toxicity and/or immune response), we checked the safety profile of IM21. 7c based LNPs. First, we observed no mortality during our in vivo injections both IV and IM. We also quantified the pro-inflammatory response of the new IM21.
Before Buffered Oxide Etching (BOE) Before partially etching the sacrificial layer beneath the junctions, the current-voltage characteristics of the different sensors were first measured and plotted. In addition to the width of the junction and the concentration of 𝑁 𝐴 acceptor atoms, the sensitivity to light and the presence of holes in the polysilicon layer can affect the characteristics of the sensors. The first electrical tests consisted in measuring the current-voltage characteristic of a number of identical 300 × 300 μm 2 sensors with a 𝑝 doping level of 𝑁 𝐴 ≈ 2 × 10 18 cm -3. These tests were performed on the same wafer and under the same operating conditions (room temperature, absence of light, etc. ). The dispersion of the data around the mean curve does not exceed 1. 5% in the detection (𝐼 = 0.
Methods This study protocol was registered on 6th April 2020 in the database of clinical trials (clinicaltrials. gov) under the registration number NCT04334603 (protocol version 2) (https://clinicaltrials. gov/ct2/show/NCT04334603). Trial registration includes all components of the World Health Organization Trial Registration Data Set, as recommended by the International Committee of Medical Journal Editors. A SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) checklist  11.
Each participant was given a logbook with photographic and written instruction on how to perform and progress each exercise. After these sessions, patients will start training in their home environment (20 exercise sessions). Every exercise session completed by the participant will be recorded by the smartwatch and uploaded to the Polar Flow application (Polar Flow, Polar Electro Ltd, Kempele, Finland). Participants will be telephoned every week to monitor progress. During phone calls, a semistructured interview will be conducted with the following objectives: to verify adherence to the exercise prescription (crossing self-reported information with data gathered from the heart rate monitor of the smartwatch), to identify problems/barriers to achieving the exercise goals, to provide training-specific advice for the adaptation of the exercise program on the patient's home environment, adjust ExT intensity and accomplish the recommended prescription, and to provide counselling for lifestyle modification.
Assessments Demographic and clinical data Sociodemographic and clinical data (including lipid profile, hemoglobin A 1c smoking status, and office blood pressure) will be captured from patients' files and/or during the CR consult. Clinical files might also be used to complete and/or confirm the patient's profile. The following information will be recorded: age, gender, marital status, educational level, HF diagnosis (etiology, left ventricular ejection fraction, and New York Heart Association functional class), medication and comorbidities. Changes in medication throughout the study will be recorded.
Data collection, management, and monitoring The collection, storage, and use of data for the research purpose will be explicitly authorize by patients in the signed consent form. All documents will be stored securely in confidential conditions and will only be accessible only by the study investigators. Patients will be identified at database and project specific documents by the study participant number. A cloud-based platform will be designed and open to all project members, to centralize data into a repository. All hard-copy files will be stored in a securely locked filing cabinet. Research fundings will be disseminated through peer reviewed journals with impact to the scientific community, and public presentations (to clinicians, to academic audiences, and in national and international meetings).
Pragmatic trials can test the same intervention as an explanatory trial, but they are conducted in real-world clinical practice settings, with typical patients and by qualified clinicians. For example, we will include patients with peripheral arterial disease, atrial fibrillation, cardiac implanted devices, and older patients, who are generally excluded from the CR studies. To our knowledge, this is the first study performed in Portugal with HF patients, that will study a home-based CR program using accessible and low-cost technology. We expect that this study can contribute to increasing the awareness of the importance of CR in HF and to provide data on different modalities of delivering CR. Each of these options should be considered in the local practice healthcare unit and to the individual HF patient to address common barriers to delivering CR such as lack of resources, and geographical and travelling constraints.
Similar rates of Pa eradication have been reported, despite differing study designs, eradication definitions and follow-up times  [ 9 , 10 ]. Aztreonam lysine for inhalation solution (AZLI) is a lyophilized formulation of the monobactam antibiotic aztreonam approved for the treatment of chronic Pa infection in pwCF aged 6 years and above  [11]. Colistimethate sodium (colistin), levofloxacin and tobramycin are inhaled antibiotics also approved for the treatment of chronic Pa infection in pwCF  [12]. Currently, however, no inhaled antibiotic is approved specifically for the treatment of new-onset Pa infection in pwCF in Europe and the USA  [12]. The ALPINE open-label study (ClinicalTrials. gov: NCT01375049) demonstrated that a 28-day course of AZLI (28-day AZLI) 75 mg three times daily in paediatric pwCF who had newly acquired Pa infection resulted in eradication rates similar to those reported for other inhaled antibiotics (75.
Study design ALPINE2 was a randomized, double-blind, multicentre phase 3b study (ClinicalTrial. gov: NCT03219164; EudraCT: 2016-002749-42) conducted at 53 centres in 12 countries between 28 November 2017 and 23 September 2021. Eligible pwCF were enrolled and randomized (1:1) to receive 75 mg AZLI three times daily for either 28 days or 14 days followed by 14 days of placebo-to-match. Randomization was achieved via an interactive web response system and pwCF were stratified by age group (3 months to < 2 years old, 2 to < 6 years old, 6 to < 18 years old). The study design outlining the study treatment phase, primary Pa eradication phase and the follow-up period is shown in Fig. 1. Respiratory samples were collected from pwCF at each visit and samples were cultured for Pa at the local and central laboratory.
Study outcomes The primary endpoint assessed the proportion of pwCF with primary Pa eradication at 4 weeks following the last AZLI dose. Primary Pa eradication was defined as having all Pa -negative cultures during the primary Pa eradication phase (14-day AZLI: week per central laboratory, and in pwCF without mucoid Pa phenotype at baseline. Secondary endpoints were: 1) median time from primary Pa eradication to Pa recurrence during the 108-week follow-up period; 2) median time to Pa eradication in a subset of the ALPINE2 population that matched the criteria of the efficacy analysis population in the tobramycin nebulizer solution (TNS) ELITE study  [20]  ; and 3) the proportion of pwCF with primary Pa eradication in the 14-day AZLI group compared with historical pooled data for Pa eradication in pwCF treated with 28-day TNS 300 mg twice daily  [ 21 , 22 ].
Acknowledgments Gilead Sciences, Inc. (Foster City, CA, USA ) would like to acknowledge all participating ALPINE2 study site investigators and thank them for their important contributions to the study and participant recruitment:  Federico Alghisi ,  Marina Aloi ,  Rodolfo Amaro-Galvez ,  Oscar Asensio de la Cruz ,  Fadi Asfour ,  Lea Bentur-Alkobi ,  Hugh Black ,  Hannah Blau ,  Hedwige Boboli ,  Richard Brooker ,  Daniel Brown ,  Stephanie Bui ,  Alan Cade ,  Silvia Castillo-Corullón ,  Andreas Claass ,  Jane Clarke ,  Malena Cohen-Cymberknoh ,  Andrew Colin ,  Carla Colombo ,  Jordi Costa i Colomer ,  Salvatore Cucchiara ,  Isabel Delgado Pecellin ,  Maria Dowell ,  Allen Dozor ,  Ernst Eber ,  Helmut Ellemunter ,  Amparo Escribano ,  Michael Fayon ,  Erol Gaillard ,  Silvia Gartner ,  Michele Gerardin ,  Francis Gilchrist ,  Brenda Giles ,  Anne Griffiths ,  Eric Haarman ,  Laurence Hanssens ,  Raj Jayaraj ,  Alison Jobling ,  David Josey ,  Sonal Kansra ,  Thomas Keens ,  Eitan Kerem ,  Alexander Kiefer ,  Nathan Kraynack ,  Christopher Landon Julian Legg ,  Salvatore Leonardi ,  Galit Livnat-Levanon ,  Vincenzina Lucidi ,  Carmen Luna ,  Ngoc Ly ,  Anirban Maitra ,  Susanna Mc-Colley ,  Jonathan McCormick ,  Kathleen McKie ,  Meir Mei Zahav ,  Volker Melichar ,  Catriona Middleton ,  Ronald Morton ,  Prasad Nagakumar ,  Stuart Nath ,  Patrick Oades ,  Christopher O'Brien ,  Hanne Olesen ,  Mustafa Osman ,  Giulia Paiola ,  Caroline Pao ,  Estela Perez Ruiz ,  Isabelle Pin ,  Dario Prais ,  Anne Prendiville ,  Valeria Raia ,  Carolyn Robinson ,  Gary Ruiz ,  Marta Ruiz de Valbuena ,  Iman Sami-Zakhari ,  Karen Schultz ,  Louis Scott ,  Marianne Skov ,  Elena Spinelli ,  Florian Stehling ,  Harm Tiddens ,  Christian Timke ,  John Tsanakas ,  Stijn Verhlust ,  Sonia Volpi  and  Karin Yaacoby-Bianu.
Acknowledgments: We gratefully acknowledge funding from the following French granting agencies:  French Agence Nationale de la Recherche  ( StaphEscape  project  ANR-16-CE15-0013 ), and the  Fondation pour la Recherche Medicale  ( DBF20161136769 ). We thank  Myriam Gominet  ( Institut Pasteur ) for the construction of the S. aureus RN450 fakB1-repaired strain.
Statistical analysis Categorical data were represented with numbers and proportions. For numerical data, normality was assessed using histograms and the Shapiro-Wilk test. Normally distributed data were represented by means and standard deviations, and abnormally distributed data by medians and interquartile ranges (IQRs). The revision-free implant survival was calculated at the 10-year follow-up, using a revision for any cause as the event and the time until revision or final follow-up as the survival time. Patients that were deceased before reaching 10-year follow-up or could not be contacted were censored. For the radiological assessment, reliability between the first two authors analyzing the radiographs was assessed using the interclass correlation (ICC) for the angle measurements and Cohen's Kappa (k) for the grades.
had better outcomes than those whose kidney had not been removed. For patients treated with sunitinib, the results were more similar between the groups with and without prior kidney removal. However, statistical tests did not find any significant differences. The JAVELIN Renal 101 trial is registered on ClinicalTrials. gov as NCT02684006. Ó 2023 The Author(s). Published by Elsevier B. V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4. 0/). Renal cell carcinoma (RCC) accounts for approximately 80% of all kidney cancers  [1]. Patients with metastatic (M1) RCC (mRCC) at diagnosis, which is termed synchronous metastasis and represents approximately one-third of RCC cases, have poor prognosis, with a 5-yr survival rate of 12-15%  [1] [2] [3] [4] [5].
To the best of our knowledge, no analysis of patients initially diagnosed with stage IV RCC with M1 disease who underwent CN followed by first-line ICI-containing combination treatment has been reported. In the phase 3 JAVELIN Renal 101 trial (NCT02684006), first-line avelumab (anti-PD-L1 antibody) + axitinib (VEGFR inhibitor) significantly prolonged PFS versus sunitinib in patients with advanced RCC  [11, 12] , leading to regulatory approvals worldwide. In this post hoc analysis, we investigated the effect of prior CN on efficacy outcomes in patients from JAVELIN Renal 101 who were initially diagnosed with M1 disease. The JAVELIN Renal 101 study design has been published previously  [11, 12]. In brief, patients with untreated advanced RCC were randomized 1:1 to receive either avelumab 10 mg/kg every 2 wk + axitinib 5 mg twice daily, or sunitinib 50 mg once daily for 4 wk (6-wk cycle).
In post hoc analyses, efficacy outcomes were assessed in subgroups of patients in the avelumab + axitinib and sunitinib arms who presented with M1 disease at diagnosis who were grouped by receipt of prior CN (yes vs no). Data from the third interim analysis were analyzed (data cutoff April 28, 2020; minimum follow-up duration 28 mo). Hazard ratios (HRs) for PFS according to investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) 1. 1 and for OS were calculated using multivariable Cox regression analysis. Odds ratios for the objective response rate (ORR; confirmed complete or partial response; investigator assessment per RECIST 1. 1) were calculated using logistic regression. For the multivariable Cox and logistic regression analyses, baseline characteristics included in the model were: age, Eastern Cooperative Oncology Group (ECOG) performance status, International Metastatic RCC Database Consortium risk group, geographic region, and PD-L1 status.
In particular, the PROBE/Southwest Oncology Group S1931 trial (NCT04510597) will compare outcomes with immunotherapy-based combination therapy in patients     Data sharing statement: On request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See https://www. pfizer. com/science/clinical-trials/trial-data-and-results for more information.
Sunitinib 1. 1 15 (0. 77-1. 70) CN = cytoreductive nephrectomy; ECOG PS = Eastern Cooperative Oncology Group performance status; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium; RECIST = Response Evaluation Criteria in Solid Tumors; SE = standard error; HR = hazard ratio; CI = confidence interval. a Two-sided.
CN = cytoreductive nephrectomy; ECOG PS = Eastern Cooperative Oncology Group performance status; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium; SE = standard error; HR = hazard ratio; CI = confidence interval. a Two-sided. E U R O P E A N U R O L O G Y 8 5 ( 2 0 2 4 ) 8 -1 2with or without prior radical or partial nephrectomy for metastatic RCC. Overall, our findings suggest that prospective studies to investigate the potential benefits of prior CN in patients who receive first-line treatment with ICI-containing combinations are warranted. has received personal and institutional advisory fees from Amgen, Bristol Myers Squibb, Eisai, Ipsen, MSD, Novartis, Pfizer, and Pierre Fabre; and has provided speaker services for Bristol Myers Squibb. Alessandra di Pietro, Mariangela Mariani, and Despina Thomaidou are employees of Pfizer and hold Pfizer stock.
A professional medical writer funded by the sponsors assisted with manuscript preparation. Acknowledgments: The authors thank the patients and their families, investigators, co-investigators, and the study teams at each of the participating centers. Patients treated at Memorial Sloan Kettering Cancer Center were supported in part by Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748). This trial was sponsored by Pfizer and was previously conducted under an alliance between Merck (CrossRef Funder ID: 10. 13039/100009945) and Pfizer. Medical writing support was provided by Katherine Quiroz-Figueroa of ClinicalThinking and was funded by Merck and Pfizer.
5) PD-L1 status Positive 96 (76) 29 (40) 114 (77) 26 (39) Negative 26 (21) 30 (42) 27 (18) 29 (43) Unknown 4 (3. 2) 13 (18) 6 (4. 1) 12 (18) CN = cytoreductive nephrectomy; ECOG PS = Eastern Cooperative Oncology Group performance status; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium; M1 = metastatic; MSKCC = Memorial Sloan Kettering Cancer Center.
Acknowledgments Funded by the  European Union  under the grant agreement " ROSAMA2″  n •  101059435  ( MSCA-PF ). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or REA. Neither the European Union nor the granting authority can be held responsible for them. This work also benefited from the investments made by the  Center of Excellence of Multifunctional Architectured Materials  " CEMAM " n •  AN-10-LABX-44-01 , and from the facilities available on the characterization platform CMTC of  Grenoble INP-UGA.
Recently, we achieved proof of concept in an individual approach: in a young woman with a history of breast cancer, myeloproliferative disorder, and rheumatoid arthritis not arising from a known genetic syndrome, we identified a germline MET mutation of unknown functional significance. The transgenic mouse model that we obtained for this MET mutation reproduced the patient's diseases and for the first time established a genetic link between auto-immune diseases and malignancies. 1  This success led us to apply the same individual approach to a 70-year-old woman with a history of multiple cancers over 30 years. In a single-center database of 447 cancer patients, 70 patients (15. 6%) had at least two different cancers, most of them with no predisposing genetic syndrome (Table  S1 ). In particular, Ms.
Methods TOCERRA and PANABA are two investigator-initiated international collaborations of registries, which aim to evaluate clinical aspects of tocilizumab and abatacept use compared to TNFi in patients with RA, and have been described previously  [23] [24] [25] [26]. The collection of clinical data in each participating registry was approved by local ethics committees and patients provided written informed consent (when required according to local law) and the collaborative study was approved by the Geneva Ethics Committee. This study included 13 registers collecting data prospectively (see Supplementary File). All patients with a diagnosis of RA established by a rheumatologist and starting treatment with TNFi, abatacept or tocilizumab between January 1st, 2009, and March 15th, 2018, with information on the presence (yes/no) or information on the dose of oral glucocorticoids at least at 2 visits, including at baseline, were considered for the present study (Figure  S1 ).
For the first main outcome evaluating if each treatment had a glucocorticoid-sparing effect, patients needed to have information on glucocorticoid usage at 12 months. For the second main outcome comparing the glucocorticoid-sparing effect between treatments, patients had to take glucocorticoids at baseline. Baseline was defined as the start of the bDMARD treatment and patients were followed up during the bDMARD treatment period. We excluded patients who initiated TNFi or abatacept before tocilizumab was commercially available (2009) to prevent confounding by time trends. Patients could be included multiple times if they were treated by more than one of the included classes of bDMARDs during the course of their disease. Only registries with available data from patients on TNFi and at least one other bDMARD (tocilizumab and/or abatacept) were included.
As an observational study, there may be residual confounding despite our efforts to adjust for potential confounders. Finally, only patients with information on glucocorticoids intake could be included. While this may limit the generalisability of our findings to patients with similar characteristics as the excluded patients (external validity), this is unlikely to introduce bias in our comparisons. Our analysis included data from routine clinical practice visits, and it is improbable that health professionals or patients would have selectively entered data in one treatment group versus another. Strengths of this study are that we were able to analyse a large cohort of patients, with an important number of covariates, a long duration of follow-up, that we were able to compare three different bDMARDs and that it represents real-life patients.
ROB-FIN is funded by AbbVie, Hospira, BMS, MSD, Pfizer, Roche and UCB. Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) database is sponsored by public and industrial support (http://scqm. ch/en/sponsoren/). DANBIO was partially supported by public and private funding (AbbVie, Biogen, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB). ARTIS is supported by agreements between Karolinska Institutet and Abbvie, BMS, MSD, Eli Lilly, Pfizer, Roche, Samsung Bioepis and UCB, mainly regarding the safety monitoring of bDMARDs in rheumatology.
This technique provides high accuracy (SE/SPE 94%/100%, AUC 0. 97) in HFpEF detection considering a stress-PCWP $25 mmHg. 3  Recently, to avoid the use of the supine cycle ergometer machine in all patients, van de Bovenkamp There is limited evidence from real-world studies of the application of diastolic echocardiographic stress test, despite emerging data in the field. 3, 110, [113] [114] [115]  In our algorithm, we have considered exercise PCWP $25 mmHg measured by exercise right heart catheterization as the gold standard to perform an invasive diagnosis of HFpEF because of the large experience in the literature using this technique. 3, 110, 114  Currently, many symptomatic patients affected by HFpEF do not have appropriate diagnosis and the management of these patients burdens the healthcare systems with useless examinations and specialist consultations.